Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.62 |
| ▸ | MMP9 | P14780 | 4/20 | 0.62 |
| ▸ | TGM2 | P21980 | 1/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | MMP7 | P09237 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | CTSL | P07711 | 6/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089183 | 0.92 | MMP2 (0.58) | MMP2MMP9TGM2MMP1MMP3 | |
| SCHEMBL8063420 | 0.90 | MMP2 (0.52) | MMP2MMP9TGM2MMP1MMP3 | |
| SCHEMBL5655210 | 0.89 | MMP2 (0.75) | MMP2MMP9TGM2MMP1MMP3 | |
| SCHEMBL3619933 | 0.88 | MMP2 (0.80) | MMP2MMP9TGM2MMP1MMP3 | |
| SCHEMBL8066137 | 0.86 | MMP2 (0.50) | MMP2MMP9TGM2MMP1MMP3 | |
| SCHEMBL27650763 | 0.83 | MMP2 (0.62) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL29027528 | 0.82 | TGM2 (0.62) | TGM2CTSLHDAC1HDAC2 | |
| SCHEMBL29027530 | 0.82 | TGM2 (0.62) | TGM2CTSLHDAC1HDAC2 | |
| SCHEMBL8057120 | 0.81 | MMP2 (0.68) | MMP2MMP9TGM2MMP1MMP3 | |
| SCHEMBL13405072 | 0.81 | MMP2 (0.68) | MMP2MMP9TGM2MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203420-A1 | HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100093811-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-04-15 | — | — | US | disclosed |
| WO-2009042093-A1 | HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093811-A1 | HIV PROTEASE INHIBITORS | PRSS1, FURIN, SERPINB1 | MMP2 72/4885MMP9 58/4885TGM2 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.